CD8A and non-small cell lung carcinoma: As a reference, we used the recent work of Liu et al.26, which consisted of scRNA-seq data of CD8+ TILs recovered from patients with non-small-cell lung cancer (NSCLC) subjected to ICB therapy (anti-PD-1 antibody treatment)26.